Item 8.01 Other Items.
On March 30, 2020, MyoKardia, Inc. issued a press release titled "MyoKardia
Announces Mavacamten Treatment Well Tolerated and Significantly Reduced
Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic
Cardiomyopathy Patients." A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release, dated March 30, 2020.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses